KRAS Mutant Screening for Small-Molecule Inhibitor Discovery 

KRAS is one of the most important yet challenging targets in oncology. Mutations such as G12C, G12D and G12V drive tumour growth in multiple cancer types and remain a major focus for the development of next-generation small-molecule inhibitors and antagonists with the potential to deliver improved anti-tumour activity.

Tebubio offers validated biochemical assays for KRAS inhibitor or antagonist screening, enabling the identification, characterisation and profiling of compounds targeting clinically relevant KRAS mutants.

Available assays:

Figure 1: Schematic representation of the mechanism of the KRAS(G12C) Nucleotide Exchange Assay Kit.

Get Dedicated Results

Hit identification

Screening of compound libraries

Lead optimization

IC50 determination

Mechanism-of-action confirmation

Comparative profiling across targets

Explore Small Molecule CRO Services

Go beyond a single assay. Explore complementary CRO capabilities for small molecule discovery, including biochemical assays, cellular validation, biomarker profiling and predictive in vitro models, and build the evidence needed to advance your compounds.

Small Molecule Drug Discovery →

Tebubio Laboratory Services Powered by BPS Bioscience

One partner, every step of discovery.

As BPS Bioscience's authorised European distributor, Tebubio delivers the same validated assay kits and reagents used in our own CRO screening, so you get reliable results, whether outsourced or in-house.

Ready to Start Your Drug Discovery Program?

Whether you are working on KRAS or another therapeutic target, our Drug Discovery Services team can help you select the right assay, design your study and generate the data needed to move your project forward.

  • References

    Article content created by Tebubio using courtesy materials provided by BPS Bioscience.